Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Extrawell Pharmaceutical Holdings Days Payable?
Extrawell Pharmaceutical HoldingsHKSE:00858 Days Payable is 60.35 as of Mar. 2026, which is 10% below its 10-year median of 66.97. The stock has 5 warning signs investors should review. Among 928 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 69.72% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's Days Payable falls into.
Extrawell Pharmaceutical Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a Days Payable of 60.35 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Extrawell Pharmaceutical Holdings and its competitors. This is 10% below median its historical median of 66.97. Over the past decade, Extrawell Pharmaceutical Holdings' Days Payable has ranged from 49.40 to 269.63. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #647 out of 928 companies in the Drug Manufacturers industry, placing it in the top 69.7%.
Is Extrawell Pharmaceutical Holdings' Days Payable too high?
Extrawell Pharmaceutical Holdings' current Days Payable of 60.35 is 10% below median its 10-year median of 66.97. Over the past 10 years, this metric has ranged from a low of 49.40 to a high of 269.63. The Drug Manufacturers industry median Days Payable is 88.39. Extrawell Pharmaceutical Holdings' value of 60.35 is 31.7% below this industry median. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #647 out of 928 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Extrawell Pharmaceutical Holdings' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #647 out of 928 companies for Days Payable. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median Days Payable is 88.39. Extrawell Pharmaceutical Holdings' value of 60.35 is 31.7% below this benchmark. Historically, Extrawell Pharmaceutical Holdings' own Days Payable has ranged from 49.40 to 269.63 over the past decade. While the company's 10-year median is 66.97 vs. the industry median of 88.39, Extrawell Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extrawell Pharmaceutical Holdings's current Days Payable of 60.35 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current Days Payable is 60.35, which is 10% below median its own 10-year median of 66.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current Days Payable is 60.35, which is 10% below median its 10-year median of 66.97 and 31.7% below the Drug Manufacturers industry median of 88.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current Days Payable is 60.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
